Diligence memo · auto-generated · as of July 2, 2026
Puma Biotechnology, Inc.
Puma Biotechnology, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Puma Biotechnology, Inc. operates in Biotechnology, based in LOS ANGELES.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Puma Biotechnology, Inc. has raised $55M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $55M on 2011-10-04.
Most recent recorded round closed around 2011-10-04.
Valuation (modeled)modeled
Provath models Puma Biotechnology, Inc. at approximately $2.3B (range $170M–$5.9B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.13× the median modeled value of Series C Biotechnology companies in 2010–2012 (19 peers) — value vs value, same stage and era. Within the normal band (113% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 14.7 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 83% of Biotechnology peers (4293 compared).
Modeled value ranks above 95% of those peers.
Closest niche peers: Insmed Inc, Infinity Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Relypsa Inc, Knopp Neurosciences Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.